Steve Green

Steve Green has extensive experience in the pharmaceutical industry, specializing in rare diseases and cardiopulmonary conditions. Currently serving as a Rare Disease Account Manager in Nephrology at Calliditas Therapeutics since September 2022, Steve previously held positions as a Therapeutic Specialist at Insmed Incorporated, where responsibilities included promoting ARIKAYCE for MAC lung disease. At Bayer HealthCare, Steve successfully launched the orphan drug Adempas for PAH and CTEPH, while earlier roles at Actelion and Millennium Pharmaceuticals focused on growth and engagement in the pulmonary and cardiovascular sectors, respectively. Career highlights include ranking first nationally for Ventavis growth and compensation earnings in 2010.